Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Clinical characteristics and molecular profiling of SF3B1-mutated myelodysplastic syndrome (MDS) in a real-world practice

View Full Paper
Ask AI
Bookmark
Share

Authors

RWRoni WangGHGee Fung HowTTTertius Tuy

Discussion

Loading...

Member takes

Overview

Observational analysis found variations in prognosis for SF3B1-mutated myelodysplastic syndrome, suggesting critical aspects for risk stratification.

Key Points

  • Higher co-mutation counts in SF3B1-mutated myelodysplastic syndrome were linked to worse prognosis.
  • The impact of SF3B1 variants on survival remains unclear; acute myeloid leukemia occurred in 2 patients.
  • Next-generation sequencing was used to identify genomic DNA mutations associated with MDS.
  • Understanding different SF3B1 variants helps in developing personalized treatment strategies.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e078https://doi.org/10.1182/blood-2025-7402
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Variant-specific SF3B1 mutations drive distinct splicing and mitochondrial dysfunction in myelodysplastic neoplasms2026
  2. 2A case of co-mutation of SF3B1 and BCR::ABL1 demonstrating an MDS-phenotype2025 · 1 citations
  3. 3Impact of different Sf3b1 mutations on hematopoietic function and erythropoiesis2025
  4. 4Not all that glitters is gold: A simple clinical score to unmask adverse SF3B1WT MDS-RS with low blast count2025
  5. 5SF3B1 mutations are associated with shorter time to first treatment in chronic lymphocytic leukemia2025